S 
Shenzhen New Industries Biomedical Engineering Co 300832.SZ · CNY
Health Care · Shenzhen · 🇨🇳 China
60.10
-0.53%
Close of 9 Nov 2026, in CNY
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
At a glance
Figures in CNY, from our data supplier.
Revenue
CN¥4.58bn
FY2016FY2025
Net income
CN¥1.62bn
FY2016FY2025
Free cash flow
CN¥1.21bn
FY2016FY2025
Shareholders' equity
CN¥9.14bn
FY2016FY2025
Income statement
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥4.58bn | CN¥4.54bn | CN¥3.93bn | CN¥3.05bn | CN¥2.55bn | CN¥2.19bn | CN¥1.68bn | CN¥1.38bn | CN¥1.14bn | CN¥922.5m |
| Gross profit | CN¥3.17bn | CN¥3.27bn | CN¥2.87bn | CN¥2.14bn | CN¥1.81bn | CN¥1.69bn | CN¥1.34bn | CN¥1.12bn | CN¥897.3m | CN¥727.0m |
| Research and development | CN¥477.8m | CN¥453.6m | CN¥366.0m | CN¥317.7m | CN¥215.0m | CN¥150.6m | CN¥119.6m | CN¥84.2m | CN¥57.2m | CN¥47.2m |
| Operating income | CN¥1.81bn | CN¥2.11bn | CN¥1.90bn | CN¥1.50bn | CN¥1.14bn | CN¥1.10bn | CN¥898.9m | CN¥807.8m | CN¥629.8m | CN¥500.9m |
| Net income | CN¥1.62bn | CN¥1.83bn | CN¥1.65bn | CN¥1.33bn | CN¥973.7m | CN¥939.1m | CN¥772.6m | CN¥694.0m | CN¥538.2m | CN¥451.7m |
| Diluted earnings per share | 2.06 | 2.33 | 2.10 | 1.69 | 1.23 | 1.19 | 1.10 | 0.88 | 0.68 | 0.64 |
Balance sheet
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | CN¥9.94bn | CN¥9.62bn | CN¥8.22bn | CN¥7.01bn | CN¥6.14bn | CN¥5.31bn | CN¥3.46bn | CN¥2.64bn | CN¥2.02bn | CN¥1.61bn |
| Cash and short-term investments | — | CN¥2.64bn | CN¥3.13bn | CN¥3.30bn | CN¥3.42bn | CN¥3.37bn | CN¥1.98bn | CN¥1.43bn | CN¥1.08bn | CN¥898.6m |
| Total liabilities | CN¥795.9m | CN¥1.04bn | CN¥678.1m | CN¥615.1m | CN¥523.5m | CN¥504.0m | CN¥318.9m | CN¥274.5m | CN¥250.0m | CN¥185.7m |
| Debt | — | CN¥4.1m | CN¥5.2m | CN¥2.2m | CN¥2.2m | — | — | — | — | — |
| Shareholders' equity | CN¥9.14bn | CN¥8.58bn | CN¥7.54bn | CN¥6.40bn | CN¥5.61bn | CN¥4.80bn | CN¥3.14bn | CN¥2.37bn | CN¥1.77bn | CN¥1.42bn |
| Shares outstanding | 786m | 786m | 786m | 786m | 791m | 786m | 704m | 786m | 786m | 704m |
Cash flow
Fiscal years
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 | FY2017 | FY2016 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | CN¥1.52bn | CN¥1.36bn | CN¥1.42bn | CN¥962.4m | CN¥773.2m | CN¥976.7m | CN¥831.7m | CN¥702.0m | CN¥524.7m | CN¥486.8m |
| Capital spending | −CN¥311.4m | −CN¥439.2m | −CN¥322.2m | −CN¥403.2m | −CN¥342.9m | −CN¥254.8m | −CN¥327.1m | −CN¥284.9m | −CN¥176.5m | −CN¥56.0m |
| Free cash flow | CN¥1.21bn | CN¥917.2m | CN¥1.10bn | CN¥559.2m | CN¥430.3m | CN¥721.8m | CN¥504.6m | CN¥417.1m | CN¥348.2m | CN¥430.8m |
| Dividends paid | −CN¥1.02bn | −CN¥786.0m | −CN¥550.0m | −CN¥471.7m | −CN¥412.4m | −CN¥619.0m | −CN¥619.0m | −CN¥101.2m | −CN¥185.2m | −CN¥55.6m |
Latest quarters
By quarter end
| Jun 2026 | Mar 2026 | Dec 2025 | Sept 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sept 2024 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | CN¥1.29bn | CN¥1.13bn | CN¥1.15bn | CN¥1.24bn | CN¥1.06bn | CN¥1.12bn | CN¥1.12bn | CN¥1.20bn |
| Gross profit | CN¥886.3m | CN¥829.3m | CN¥813.8m | CN¥860.5m | CN¥730.2m | CN¥765.0m | CN¥798.9m | CN¥864.6m |
| Operating income | CN¥509.6m | CN¥522.2m | CN¥505.9m | CN¥463.7m | CN¥380.4m | CN¥496.7m | CN¥509.4m | CN¥543.4m |
| Net income | CN¥425.7m | CN¥442.0m | CN¥415.4m | CN¥433.7m | CN¥333.6m | CN¥437.5m | CN¥444.9m | CN¥480.4m |
| Diluted earnings per share | 0.54 | 0.56 | 0.53 | 0.55 | 0.42 | 0.56 | 0.57 | 0.61 |
| Cash from operations | — | — | — | CN¥606.0m | CN¥442.0m | CN¥18.0m | CN¥398.0m | CN¥339.0m |
| Capital spending | −CN¥92.0m | −CN¥90.0m | −CN¥93.0m | −CN¥45.0m | −CN¥112.0m | −CN¥58.0m | −CN¥119.0m | −CN¥93.0m |
| Free cash flow | — | — | — | CN¥561.0m | CN¥330.0m | −CN¥40.0m | CN¥279.0m | CN¥246.0m |
| Total assets | CN¥9.76bn | CN¥10.22bn | CN¥9.94bn | CN¥9.58bn | CN¥8.98bn | CN¥9.73bn | CN¥9.62bn | CN¥8.84bn |
| Cash and short-term investments | — | — | — | CN¥2.26bn | CN¥1.63bn | CN¥2.48bn | CN¥2.64bn | CN¥2.59bn |
| Debt | — | — | — | CN¥1.8m | CN¥1.6m | CN¥1.3m | — | — |
| Shareholders' equity | CN¥8.97bn | CN¥9.49bn | CN¥9.14bn | CN¥8.74bn | CN¥8.31bn | CN¥9.00bn | CN¥8.58bn | CN¥8.12bn |
Growth per year
Compound annual rate
| 3 years | 5 years | 10 years | |
|---|---|---|---|
| Revenue | 14.5% | 15.8% | 20.1% |
| Operating income | 6.3% | 10.5% | 20.9% |
| Net income | 6.9% | 11.5% | 20.6% |
Average margins
Over each period
| 1 year | 3 years | 5 years | 10 years | |
|---|---|---|---|---|
| Gross margin | 70.7% | 71.1% | 71.8% | 73.4% |
| Operating margin | 43.0% | 45.5% | 45.9% | 47.4% |
| Net margin | 37.8% | 40.0% | 40.1% | 41.4% |
Valuation history
At each fiscal year end
| FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|
| Price to earnings | 27.3 | 30.4 | 37.2 | 29.7 | 35.8 | 58.2 |
| Price to sales | 9.7 | 12.3 | 15.6 | 12.9 | 13.7 | 24.9 |
Dividends and splits
Per share, in the currency the company pays
Paid for 6 years. Last went ex-dividend on 27 May 2026.
| FY2026 | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | |
|---|---|---|---|---|---|---|---|
| Paid in the year | 1.20 | 1.30 | 1.00 | 0.70 | 0.60 | 0.526 | 0.79 |
- 19-for-10 split · 21 May 2021
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.